search
Back to results

Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents

Primary Purpose

Self Harm, Suicidal Ideation

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
tVns Program
Phone App Program
tVNS and Phone App Program
Enhanced Treatment as Usual
Sponsored by
University of Notre Dame
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Self Harm focused on measuring Self Harm, Suicide Prevention

Eligibility Criteria

13 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Aged between 13 and 17 years, Attend in person meetings in South Bend, IN or Rochester, NY. and, Two of the following which will be scored during the phone screen: Engaged in non-suicidal self-harm 3 times in the past 6 months or more than 5 times in their life time, with one occurrence in the past year. Show high scores on emotional dysregulation Show high scores on social isolation Show high scores on impulsivity Show high scores on depression Engage in alcohol or other substance use Exclusion Criteria: Parent reported autism or schizophrenia Implanted pacemaker or cardiac defibrillator, other implanted or metallic device Pregnant or breast feeding History of seizures or epilepsy TMJ Disorder Bells' Palsy Impaired cranial nerve function Facial Pain

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Sham Comparator

    Arm Label

    tVNS Program

    Phone App Program

    tVNS and Phone App Program

    Enhanced Treatment as Usual

    Arm Description

    Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.

    Adolescents will use a specially designed phone app to communicate with peers to help them cope with emotions, and to foster connection with peers to establish social connections. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey. The phone app will not be monitored during the night. If your adolescent needs immediate care during the night, please call 911 or your doctor's emergency contact number.

    Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.

    Enhanced TAU participants will be referred to and have access to available services within the community and, in addition to reports of their daily experiences via the sham app, will be called weekly to complete risk assessments during the active 30-day intervention stage.

    Outcomes

    Primary Outcome Measures

    Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days
    Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face interview with a trained staff member to assess their level of non-suicidal self-injury, suicide ideation, and suicide attempts. In addition, we will collect measures of psychophysiological reactivity (heart rate variability, cardiac pre-ejection period) to emotional challenge. All participants will complete the same tasks at subsequent visits (post-treatment, on-year follow-up) and it is hoped that teens who have used the tVNS device for the 30-day intervention period will show improved responses. For the rate of change, we will use percentile ranking vis-a-vis national norms.
    Improved Reports of Social Isolation and Loneliness
    Each participating teen will complete questions regarding feelings of loneliness and social isolation on the Qualtrics survey while in the lab at each visit. We are using the 8-item UCLA loneliness scale to measure this in each teen. Some teens will be assigned to using the peer support phone app where they will be matched with another teen in this study. They will play a cooperative game with each other, and be able to text and share thoughts, feelings, etc. with each other. This app will hopefully improve teen's self-reported feelings of isolation and loneliness. For the rate of change, we will use percentile ranking vis-a-vis national norms.
    Improved Results from Participant's Typical Treatment
    Teens who are not placed in one of the active intervention groups will still be able to access our phone app which allows them to play a non-cooperative game on their own, and they are able to text with our team members during regular business hours. The added support will hopefully help their current treatment plan to improve their thoughts and behaviors in regard to suicidal ideation and self-harm. For the rate of change, we will use percentile ranking vis-a-vis national norms.

    Secondary Outcome Measures

    Adherence to tVNS and Phone App intervention from Baseline to 30 days.
    Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusiveness, and favorability of both the device and the phone app.

    Full Information

    First Posted
    October 6, 2022
    Last Updated
    June 28, 2023
    Sponsor
    University of Notre Dame
    Collaborators
    University of Rochester
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05602779
    Brief Title
    Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents
    Official Title
    Leveraging Noninvasive Transcutaneous Vagus Nerve Stimulation and Smartphone Technology to Reduce Suicidal Behaviors and Suicide Among Highly Vulnerable Adolescents
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 1, 2023 (Anticipated)
    Primary Completion Date
    April 15, 2027 (Anticipated)
    Study Completion Date
    September 30, 2027 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Notre Dame
    Collaborators
    University of Rochester

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence. Current face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents' digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these digitally-delivered interventions could reach far more adolescents at far lower cost than current approaches.
    Detailed Description
    Over the past two decades, suicide rates have increased nearly 35% in the U.S., with upward trends in nearly all demographic groups. Further increases have occurred since the COVID-19 pandemic began. Despite ambitious goals for reducing suicides and significant federal and private investment, suicide rates continue to rise unabated. To date, the predominant approach to mitigating suicide risk in the U.S. is secondary prevention. Typically, these programs identify risk of recurrence among those who have already attempted suicide at least once. Although secondary prevention is crucial, the majority of deaths by suicide occur on first attempt. Thus, targeted primary prevention earlier in development is essential. Most current primary prevention programs are intensive, expensive, and delivered by highly trained mental health providers, who are in short supply. Traditional face-to-face therapy is also unavailable to many who live in underserved communities, and disliked by adolescents, who much prefer digital delivery on their devices. This high-risk, high-reward proposal addresses these limitations and needs. We use an experimental therapeutics approach to evaluate the independent and combined efficacies of two unconventional but scalable interventions: transcutaneous vagus nerve stimulation (tVNS) to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. These low-cost interventions, which hold strong promise but have not been used before, can reach large numbers of adolescents, with much potential to reduce prospective suicide risk. We will enroll 212 adolescents, ages 13-17 years, who show elevations on at least two prominent risk factors for suicide (e.g., self-injury, maltreatment). Using a 2 × 2 design, adolescents will be assigned randomly to receive 30 days of treatment with: tVNS to target emotion dysregulation, a peer-support phone app to target social isolation, tVNS + a peer-support phone app, or enhanced treatment as usual with monitoring and access to resources. Intervention effects on mechanisms (emotion dysregulation, social isolation) proximal efficacy signals (e.g., physiological reactivity, self-harm) and target outcomes (suicidal ideation, suicidal behaviors) will be evaluated immediately post-intervention and at one-year follow-up. Treatment data will be monitored daily to fine-tune dosing of both interventions. This transformative and innovative proposal tests two novel, scalable preventive interventions designed to "meet adolescents where they are" by using digital technologies to address core mechanisms of suicide risk.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Self Harm, Suicidal Ideation
    Keywords
    Self Harm, Suicide Prevention

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    There will be four distinct treatment groups, each participant will be randomly assigned to one of the four groups.
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    212 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    tVNS Program
    Arm Type
    Experimental
    Arm Description
    Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
    Arm Title
    Phone App Program
    Arm Type
    Experimental
    Arm Description
    Adolescents will use a specially designed phone app to communicate with peers to help them cope with emotions, and to foster connection with peers to establish social connections. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey. The phone app will not be monitored during the night. If your adolescent needs immediate care during the night, please call 911 or your doctor's emergency contact number.
    Arm Title
    tVNS and Phone App Program
    Arm Type
    Experimental
    Arm Description
    Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
    Arm Title
    Enhanced Treatment as Usual
    Arm Type
    Sham Comparator
    Arm Description
    Enhanced TAU participants will be referred to and have access to available services within the community and, in addition to reports of their daily experiences via the sham app, will be called weekly to complete risk assessments during the active 30-day intervention stage.
    Intervention Type
    Device
    Intervention Name(s)
    tVns Program
    Intervention Description
    Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
    Intervention Type
    Other
    Intervention Name(s)
    Phone App Program
    Intervention Description
    Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.
    Intervention Type
    Combination Product
    Intervention Name(s)
    tVNS and Phone App Program
    Intervention Description
    Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
    Intervention Type
    Other
    Intervention Name(s)
    Enhanced Treatment as Usual
    Intervention Description
    Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.
    Primary Outcome Measure Information:
    Title
    Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days
    Description
    Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face interview with a trained staff member to assess their level of non-suicidal self-injury, suicide ideation, and suicide attempts. In addition, we will collect measures of psychophysiological reactivity (heart rate variability, cardiac pre-ejection period) to emotional challenge. All participants will complete the same tasks at subsequent visits (post-treatment, on-year follow-up) and it is hoped that teens who have used the tVNS device for the 30-day intervention period will show improved responses. For the rate of change, we will use percentile ranking vis-a-vis national norms.
    Time Frame
    30 Days
    Title
    Improved Reports of Social Isolation and Loneliness
    Description
    Each participating teen will complete questions regarding feelings of loneliness and social isolation on the Qualtrics survey while in the lab at each visit. We are using the 8-item UCLA loneliness scale to measure this in each teen. Some teens will be assigned to using the peer support phone app where they will be matched with another teen in this study. They will play a cooperative game with each other, and be able to text and share thoughts, feelings, etc. with each other. This app will hopefully improve teen's self-reported feelings of isolation and loneliness. For the rate of change, we will use percentile ranking vis-a-vis national norms.
    Time Frame
    30 Days
    Title
    Improved Results from Participant's Typical Treatment
    Description
    Teens who are not placed in one of the active intervention groups will still be able to access our phone app which allows them to play a non-cooperative game on their own, and they are able to text with our team members during regular business hours. The added support will hopefully help their current treatment plan to improve their thoughts and behaviors in regard to suicidal ideation and self-harm. For the rate of change, we will use percentile ranking vis-a-vis national norms.
    Time Frame
    30 Days
    Secondary Outcome Measure Information:
    Title
    Adherence to tVNS and Phone App intervention from Baseline to 30 days.
    Description
    Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusiveness, and favorability of both the device and the phone app.
    Time Frame
    30 Days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    13 Years
    Maximum Age & Unit of Time
    17 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Aged between 13 and 17 years, Attend in person meetings in South Bend, IN or Rochester, NY. and, Two of the following which will be scored during the phone screen: Engaged in non-suicidal self-harm 3 times in the past 6 months or more than 5 times in their life time, with one occurrence in the past year. Show high scores on emotional dysregulation Show high scores on social isolation Show high scores on impulsivity Show high scores on depression Engage in alcohol or other substance use Exclusion Criteria: Parent reported autism or schizophrenia Implanted pacemaker or cardiac defibrillator, other implanted or metallic device Pregnant or breast feeding History of seizures or epilepsy TMJ Disorder Bells' Palsy Impaired cranial nerve function Facial Pain
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Cheryl Lee, MS
    Phone
    574-631-5097
    Email
    clee21@nd.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Theodore Beauchaine, PhD
    Organizational Affiliation
    William K Warren Foundation Professor of Psychology
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    There is no plan to share individual participant data outside of the study team.

    Learn more about this trial

    Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents

    We'll reach out to this number within 24 hrs